Keywords: astrazeneca, nexium, new, data, do, change, outlook
AstraZeneca's Nexium, new data do not change outlook, says GS
Article | 24 May 2000
Although it says that limited incremental data were obtained, GoldmanSachs has retained its market outperformer rating on AstraZeneca following the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
